NEW PRODUCT: Ringza vaginal contraceptive ring

Quebec-based pharmaceutical company Duchesnay has announced the launch of a new vaginal contraceptive ring.

Ringza, which was developed in collaboration with the non-profit Population Council, is a slow-release silicone vaginal ring designed to be used for up to one year. The ring is completely patient controlled and can be inserted or removed without the help of a clinician, while also cutting down pharmacy trips to a single visit per year.

The company says Ringza is the first Canadian use of segesterone acetate, a recently approved progestin. Ringza releases a daily dose of 0.15 mg segesterone acetate as well as 0.013 mg of ethinyl estradiol.

“Duchesnay is redefining innovation for Canadian women. As a Canadian company based in Quebec . . . we are proud to make Canada the first country to launch Ringza and lead the way for the world,” Édith Sirard, Duchesnay’s director of sales and marketing said in a news release. 

“This is reinforcing our commitment to advancing women’s health and a significant step forward in expanding access to meaningful innovative solutions that prioritize women’s evolving needs in 2026 and beyond.”